|
|
|
|
Vol. 58, Issue 2, 288-299, August 2000
Department of Pharmacology, Medical School, The University of
Michigan, Ann Arbor, Michigan
The genotype at the NAT1* locus of an interethnic
population of 38 unrelated subjects was determined by direct sequencing of 1.6-kb fragments amplified by PCR. The coding exon alone and together with the 3' noncoding exon of the wild-type
(NAT1*4) and the three mutant alleles
(NAT1*10, *11, and *16)
detected was expressed in Escherichia coli and COS-1
cells, respectively, and the cytosolic fraction of mononuclear
leukocytes from NAT1*4/*4 and NAT1*10/*10
homozygotes was also isolated. Recombinant and leukocyte cytosolic
preparations were thoroughly characterized by
N-acetylation activity with several NAT1-specific and
-selective substrates, as well as by steady-state kinetics with varying
amounts of the substrate (fixed acetyl CoA) and acetyl CoA (fixed
substrate), thermodynamics, stability, and protein immunoreactivity
with a polyclonal human anti-NAT1. The polyadenylation signal mutation in the 3' noncoding sequence of NAT1*10 affected none of
the aforementioned parameters evaluated both with recombinant
NAT1*10 and with the naturally occurring allele.
Function was also unaffected by the coding and 3' noncoding exon
mutations in NAT1*11. In contrast, the three extra
adenosines located immediately after the sixth position of the
polyadenylation signal in the 3' untranslated region of
NAT1*16 ostensibly caused disruption of the predicted secondary structure of the pre-mRNA for NAT1 16, culminating in parallel 2-fold decreases in the amount and catalytic activity of NAT1
16 in COS-1 cell cytosol. This novel finding in
N-acetylation pharmacogenetics clearly demonstrates a
direct link between reduced catalytic activity and structural
alteration in the 3' untranslated region of an NAT
variant (NAT1*16) brought about by mutation.
This article has been cited by other articles:
![]() |
L. Jiao, M. A. Doll, D. W. Hein, M. L. Bondy, M. M. Hassan, J. E. Hixson, J. L. Abbruzzese, and D. Li Haplotype of N-Acetyltransferase 1 and 2 and Risk of Pancreatic Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2379 - 2386. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fronhoffs, T. Bruning, E. Ortiz-Pallardo, P. Brode, B. Koch, V. Harth, A. Sachinidis, H. M. Bolt, C. Herberhold, H. Vetter, et al. Real-time PCR analysis of the N-acetyltransferase NAT1 allele *3, *4, *10, *11, *14 and *17 polymorphism in squamous cell cancer of head and neck Carcinogenesis, September 1, 2001; 22(9): 1405 - 1412. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Cascorbi, I. Roots, and J. Brockmoller Association of NAT1 and NAT2 Polymorphisms to Urinary Bladder Cancer: Significantly Reduced Risk in Subjects with NAT1*10 Cancer Res., July 1, 2001; 61(13): 5051 - 5056. [Abstract] [Full Text] [PDF] |
||||